Screen Readers Skip to Content

Researchers Urge More Transparency From FDA

Published: 2017-03-18
Author: Johns Hopkins University Bloomberg School of Public Health | Contact: jhsph.edu

Synopsis: Researchers create Blueprint for Transparency to advance the development of safe and effective new products.

Main Digest

As the new administration considers the future direction of the Food and Drug Administration, a group of leading researchers has created a Blueprint for Transparency at the agency to advance the development of safe and effective new products.

Related

The researchers include senior faculty from the Johns Hopkins Bloomberg School of Public Health, Harvard Medical School/Brigham and Women's Hospital, Yale Medical School, and Yale Law School. The project was organized by Joshua Sharfstein, MD, Professor of the Practice at the Bloomberg School.

Sharfstein and Michael Stebbins, PhD, of the Laura and John Arnold Foundation, have authored an overview of the Blueprint in JAMA, released online March 13.

The full report, Blueprint for Transparency at the U.S. Food and Drug Administration, is being released simultaneously online at http://www.jhsph.edu/blueprintFDA

"FDA is more than an agency that makes regulatory decisions," says Sharfstein, a former FDA Principal Deputy Commissioner. "It is also a repository for scientific analysis and data that, if more widely available, would improve understanding of existing therapies, the pharmaceutical pipeline and opportunities for innovative product development."

The report makes 18 recommendations in five principal areas:

All of the Blueprint's recommendations can be implemented by FDA without new legislation from Congress, and all respect legal protections for trade secrets.

"Enhancing Transparency at the U.S. Food and Drug Administration: Moving Beyond the 21st Century Cures Act" was written by Joshua M. Sharfstein and Michael Stebbins. The full Blueprint for Transparency was written by the FDA Transparency Working Group which includes Sharfstein as well as James Dabney Miller, Anna L Davis, Caleb Alexander, Brian Smith and Anam Chaudry of the Bloomberg School; Joseph S. Ross of Yale Medical School; Margaret E. McCarthy of Yale Law School; and Aaron Kesselheim of Brigham and Women's Hospital/Harvard Medical School.

The Blueprint for Transparency is supported by a grant from the Laura and John Arnold Foundation.

In Other News:

You're reading Disabled World. See our homepage for informative disability news, reviews, sports, stories and how-tos. You can also connect with us on social media such as Twitter and Facebook or learn more about Disabled World on our about us page.

Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.


Cite This Page (APA): Johns Hopkins University Bloomberg School of Public Health. (2017, March 18). Researchers Urge More Transparency From FDA. Disabled World. Retrieved October 17, 2021 from www.disabled-world.com/medical/pharmaceutical/fda/transparency.php